Oncology / Cancer
15 Results were found on Technologies
Sub Category Name
Targeting Bone Neoplasms and Other Cancers with Novel Combined Anticancer and Anti-Angiogenic Polymer Therapeutics
Anti-cancer NanoTherapyUtilizing unique nano-technology to develop targeted combination nanomedicines that were shown to be synergistic, effective and safe for treating cancer TechnologyWe have developed a new platform technology for the treatment of cancer and bone metastases using combined targeted nano-sized polymers that deliver chemotherapeutics creating a new class of effective and safer molecules. The novel […] Read More >
Biomarkers for Risk Assessment in Colorectal Cancer Patients
Mortalin (also known as GRP75 and mitochondrial stress protein 70) is a ubiquitously expressed mitochondrial chaperone related to the cytosolic heat shock protein 70 (HSP70). It protects cells from senescence and apoptosis and is overexpressed in most cancer cells. We discovered that cell resistance to complement-dependent cytotoxicity depends on mortalin and that mortalin is released […] Read More >
Novel Integrase Based Cancer Treatment Technology
We have developed a new gene therapy technology for specific cancer cells killing and validated both efficacy and safety superiority of the proposed system over the conventional one in lung cancer mice model. The proposed system offers advantages over already known counterparts and may therefore be developed into a safer and efficient human cancer treatment […] Read More >
An Oncolytic Virus That Exploits Immune Defects of Cancer Cells
An oncolytic virus for tumors of different etiology presenting defects in interferon signaling, designed as a potent, specific and safe therapy. Promising in-vivo murine melanoma model shows potential for development as a mono or an add-on to chemotherapy or check-point inhibitors. UNMET NEEDOn Nov. 2015 the FDA approved the first oncolytic virus based treatment. Oncolytic […] Read More >
A Novel Nanoparticle that Selectively Delivers RNAi Oligonucelotides to Tumors, Preventing Side Effects to Tissues
UNMET NEEDPancreatic cancer numbers among the most aggressive cancers known today. The overwhelming majority of pancreatic cancer patients pass away within just a year of diagnosis. However, a small minority of patients may live several years with the disease. Our findings pinpoint the inverse correlation between a known oncogene (PLK1) and the expression of an […] Read More >
Therapeutic Vaccine for the Treatment of Cancer
An active cancer vaccine strategy targeting tumor-associated carbohydrate antigens expressed on tumor cells using biomimetic glyconanoparticles generated from unique red blood cells. The resulting sustained immune response inhibits tumor growth. THE NEED While envisioned already in 1891, only a few cancer vaccines have been approved by the FDA thus far. The key barriers to their […] Read More >
Macrolid Induced Correction of Premature Stop Codons: A novel Treatment for Colorectal Cancer
Restoration of premature termination codons (PTCs) caused by nonsense mutations for the treatment of Familial Adenomatous Polyposis. The Need Familial Adenomatous Polyposis (FAP) is a high penetrance devastating syndrome manifested by dozens to thousands of colonic adenomas. FAP patients require tight supervision and eventually undergo surgery, to prevent inevitable development of colorectal cancer (CRC) by […] Read More >
Anti-Cancer Nanotherapy: Targeted Potent Conjugated BRAF/MEK Inhibitors
In the last decade, deep understanding of key oncogenes and signaling pathways, involved in cancer pathogenesis and progression were achieved, leading to new treatment options. However, the number of patients with metastatic melanoma continue to rise. This may be attributed to the prolonged life-span of cancer patients with primary tumors, enabling metastatic spread later on. […] Read More >
Novel Bcr-Abl1 Inhibitors for Treating Imatinib Resistance Cancer
The BCR-ABL1 fusion gene is the hallmark of the Philadelphia chromosome-positive (Ph+) leukemia, creating a constitutively active ABL1 tyrosine kinase. Current therapy relies on the FDA-approved tyrosine kinase inhibitors (TKIs) such as imatinib (Gleevec®), which target the ATP binding site of the BCR-ABL1 kinase. Unfortunately, the acquisition of point mutations in the ATP binding site […] Read More >
Novel Anti-Tumor Response treatment targeting ErbB receptors and Nucleolin interactions
ErbBs subfamily receptors are mediators of cell growth signals. They have long been associated with a wide variety of lung, ovarian, colon, breast, prostate, and other carcinomas. Nucleolin is a major nucleolar protein of growing eukaryotic cells and is present on the cell surface of a range of cancers. Recently, a robust oncogenic interaction between […] Read More >
